Eagle Health Investments
Eagle Health Investments reported 27 stocks worth $603M in its 13F filing for Q2 2026, filed Aug 10, 2026. Its largest holdings are ARGX (11.8%), ICLR (8.9%) and GH (7.5%). Compared with Q1 2026, the fund opened new positions in ASND, AXSM and IONS, added to ARGX, INSM and BMRN, trimmed ICLR, GH and FTRE and sold out of BBIO, ASND and PRCT.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  ARGX Argenx SE | $70.9M | 11.8% | 76K | +81 (+0%) | 8 of 8 | |
| 2 |  ICLR Icon PLC | $53.5M | 8.9% | 308K | −50K (−14%) | 8 of 8 | |
| 3 |  GH Guardant Health Inc | $45.1M | 7.5% | 301K | −9,596 (−3%) | 5 of 8 | |
| 4 |  INSM Insmed Inc | $41M | 6.8% | 384K | +160K (+71%) | 8 of 8 | |
| 5 |  BMRN Biomarin Pharmaceutical Inc | $35.7M | 5.9% | 625K | +119K (+24%) | 8 of 8 | |
| 6 |  ILMN Illumina Inc | $33M | 5.5% | 187K | No change | 8 of 8 | |
| 7 |  SRRK Scholar Rock Hldg Corp | $30.5M | 5.1% | 555K | +61K (+12%) | 5 of 8 | |
| 8 |  PTGX Protagonist Therapeutics Inc | $30.4M | 5.0% | 248K | +69K (+38%) | 3 of 8 | |
| 9 |  RARE Ultragenyx Pharmaceutical in | $29.5M | 4.9% | 884K | No change | 7 of 8 | |
| 10 |  CMPS Compass Pathways PLC | $29.2M | 4.8% | 2.1M | No change | 4 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 10, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Eagle Health Investments 13F FAQ
What does Eagle Health Investments own?
Eagle Health Investments reported 27 stocks worth $603M in its 13F filing for Q2 2026, filed Aug 10, 2026. Its largest holdings are ARGX (11.8%), ICLR (8.9%) and GH (7.5%). The table above lists every position in the filing (the top 10 without an account).
What did Eagle Health Investments buy and sell in Q2 2026?
Compared with Q1 2026: 6 new positions, 9 added to, 4 trimmed and 5 sold out. New positions include ASND, AXSM and IONS. It sold all of BBIO, ASND and PRCT.
When will Eagle Health Investments file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Eagle Health Investments's portfolio worth?
The Q2 2026 filing reports $603M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.